Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway

HER2 is a receptor tyrosine kinase and its upregulation via activating mutations or amplification has been identified in some malignant tumors, including lung cancers. Because HER2 can be a therapeutic target in HER2-driven malignancies, it is important to understand the molecular mechanisms of HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtsuka, Tomoaki, Sakaguchi, Masakiyo, Yamamoto, Hiromasa, Tomida, Shuta, Takata, Katsuyoshi, Shien, Kazuhiko, Hashida, Shinsuke, Miyata-Takata, Tomoko, Watanabe, Mototsugu, Suzawa, Ken, Soh, Junichi, Youyi, Chen, Sato, Hiroki, Namba, Kei, Torigoe, Hidejiro, Tsukuda, Kazunori, Yoshino, Tadashi, Miyoshi, Shinichiro, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5180104/
https://www.ncbi.nlm.nih.gov/pubmed/28008968
http://dx.doi.org/10.1038/srep39557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5180104/
https://www.ncbi.nlm.nih.gov/pubmed/28008968
http://dx.doi.org/10.1038/srep39557

Ejemplares similares